Skip to main content
. 2022 Feb 8;14(3):842. doi: 10.3390/cancers14030842

Figure 3.

Figure 3

Forest plot of randomized clinical trials assessing the predictive value of neoadjuvant cisplatin-based chemotherapy for overall survival in locally advanced cervical cancer. Relative risks (RR) are given with 95% confidence intervals. Neoadjuvant chemotherapy using dose-intense cisplatin-based chemotherapy ≥ 105 mg/m2/3 weeks significantly improves overall survival: RR = 0.79 (95% CI, 0.67 to 0.93); heterogeneity I2 = 29%, p = 0.21.